Literature DB >> 13591884

[A new anticoagulant derived from fibrinogen].

S NIEWIAROWSKI, E KOWALSKI.   

Abstract

Entities:  

Keywords:  ANTICOAGULANTS; FIBRIN; FIBRINOGEN

Mesh：

Substances：

Year:  1958        PMID： 13591884

Source DB:  PubMed          Journal:  Rev Hematol        ISSN： 0370-4386


× No keyword cloud information.
  23 in total

1.  [THE SIGNIFICANCE OF PROTEOLYSIS IN OBSTETRICAL DEFIBRINATION HEMORRHAGES AND THERAPY WITH TRASYLOL].

Authors:  D F STEICHELE; H J HERSCHLEIN
Journal:  Arch Gynakol       Date:  1964-04-14

2.  THE LABORATORY CONTROL OF THROMBOLYTIC THERAPY.

Authors:  C HAWKEY; M HOWELL
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

3.  ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.

Authors:  A P FLETCHER; O BIEDERMAN; D MOORE; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

4.  [THE PHYSIOLOGIC INHIBITORS OF BLOOD COAGULATION IN PATHOLOGICALLY INCREASED COAGULABILITY IN VIVO. II. SERUM INFUSION INTO THE BLOOD STREAM].

Authors:  K SCHIMPF; A CIBELIUS; R MARDINI
Journal:  Klin Wochenschr       Date:  1964-07-01

5.  Alterations in blood coagulation and hemostasis during extracorporeal circulation. II.

Authors:  A G KENDALL; L LOWENSTEIN
Journal:  Can Med Assoc J       Date:  1962-10-20       Impact factor: 8.262

6.  [Thromboelastographic studies on the blood clot structure in the Sanarelli-Shwartzman phenomenon].

Authors:  G MULLER-BERGHAUS; H J KRECKE; H G LASCH
Journal:  Klin Wochenschr       Date:  1963-03-01

7.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy.

Authors:  N U BANG; A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

8.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

9.  Problems in hemostasis during openheart surgery. IV. On the changes in the blood clotting mechanism during cardiopulmonary bypass procedures.

Authors:  H GANS; W KRIVIT
Journal:  Ann Surg       Date:  1962-03       Impact factor: 12.969

10.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.